Ifosfamide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IFEX/MESNEX KIT | — | 1987-08-14 | fda.gov ↗ |
Trials 296 · started per year
Also used as a comparator or background therapy in 166 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT01331590 Background | Jul 2011 → Oct 2014 | precursor lymphoblastic lymphoma/leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00515138 Background | May 2007 → Nov 2011 | B-cell non-Hodgkin lymphoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT06156410 Background | Oct 2023 → Nov 2027 expected | Ewing sarcoma, osteosarcoma | Children's Hospital of Philadelphia | Recruiting | No outcome recorded |
| Phase 1 | NCT05364424 Background | Nov 2022 → Oct 2025 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04151810 Background | Dec 2019 → Oct 2022 | — | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03349346 Background | Jun 2019 → Feb 2021 | diffuse large B-cell lymphoma, mediastinal malignant lymphoma | Gilead Sciences | Withdrawn | No outcome recorded |
| Phase 1 | NCT03450343 Background | Apr 2019 → Aug 2023 | diffuse large B-cell lymphoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT03212937 Background | Jul 2016 → Nov 2020 | peripheral T-cell lymphoma, not otherwise specified | National Cancer Centre, Singapore | Completed | No outcome recorded |
| Phase 1 | NCT02471911 Background | Dec 2015 → Oct 2019 | diffuse large B-cell lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT02219737 Background | Sep 2014 → May 2017 | diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01959698 Background | Apr 2014 → Jun 2020 overdue | diffuse large B-cell lymphoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01576692 Background | Apr 2012 → Oct 2014 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01884428 Background | Jul 2011 → Mar 2014 | Hodgkins lymphoma | Armando Santoro, MD | Unknown | No outcome recorded |
| Phase 1 | NCT01226849 Background | Nov 2010 → Nov 2014 | diffuse large B-cell lymphoma | Singapore General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00960063 Background | Nov 2009 → Dec 2010 | bone cancer, kidney neoplasm, neuroblastoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00822848 Background | Feb 2009 → Sep 2012 | sarcoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00742924 Background | Aug 2008 → Apr 2012 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00598169 Background | Nov 2007 → Oct 2014 | lymphoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT01300793 Background | May 2007 → Jul 2011 | B-cell non-Hodgkin lymphoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1 | NCT00439361 Background | Feb 2007 → Jun 2012 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00623077 Background | Aug 2005 → Jul 2012 | central nervous system neoplasm, kidney cancer, liver cancer, retinoblastoma +1 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT00502892 Background | Aug 2004 → Jan 2010 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003597 Background | Nov 1998 → Oct 2004 | cancer | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00004086 Background | Jun 1997 → ? | leukemia, lymphoma | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | Unknown | No outcome recorded |
| Phase 1/219 trials | ||||||
| Phase 1/2 | NCT04663347 Background | Nov 2020 → Sep 2027 expected | diffuse large B-cell lymphoma, follicular lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04425070 Background | Aug 2020 → Dec 2025 | mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Antengene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03628131 Background | Oct 2018 → Jul 2023 | childhood malignant neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03064867 Background | Jun 2017 → Aug 2022 overdue | diffuse large B-cell lymphoma | Molly Gallogly | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02018861 Comparator | Sep 2016 → Apr 2021 | B-cell neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02628405 Background | May 2016 → Sep 2021 | primary mediastinal large B-cell lymphoma | Academic and Community Cancer Research United | Unknown | No outcome recorded |
| Phase 1/2 | NCT02686346 Background | Mar 2016 → Oct 2018 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 1/2 | NCT02348216 Background | Apr 2015 → Jul 2023 | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02408042 Comparator | Apr → Nov 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma | Western Regional Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02235701 Background | Sep 2014 → May 2018 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01169636 Background | Jan 2011 → May 2017 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00788125 Background | Sep 2008 → Apr 2010 | central nervous system neoplasm, childhood germ cell tumor, childhood malignant neoplasm, extragonadal germ cell tumor +7 | City of Hope Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00601718 Background | Dec 2007 → Jun 2010 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +11 | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00354107 Background | Jan 2007 → Jan 2010 | anaplastic large cell lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00551122 Background | Nov 2006 → Apr 2013 | central nervous system neoplasm, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor | University of Southampton | Unknown | No outcome recorded |
| Phase 1/2 | NCT00147225 Background | Aug 2005 → Mar 2013 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00086944 Background | May 2004 → Jul 2006 | diffuse large B-cell lymphoma, mantle cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00093509 Background | Nov 1999 → Jul 2007 | sarcoma | Mark Dewhirst | Completed | No outcome recorded |
| Phase 1/2 | NCT00002559 Background | Jan 1994 → Jan 2003 | ovarian cancer, testicular germ cell tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 270 trials | ||||||
| Phase 2 | NCT07321912 Background | Jun 2026 → Jun 2031 expected | Ewing sarcoma, osteosarcoma | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07477457 Background | Mar 2026 → Mar 2028 expected | metastatic neoplasm, osteosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07142863 Background | Aug 2025 → Aug 2026 overdue | osteosarcoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07081022 Background | Aug 2025 → Apr 2027 expected | B-cell non-Hodgkin lymphoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06699472 Background | Oct 2024 → Sep 2026 expected | Ewing sarcoma, chemotherapy-induced toxicity | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06333314 Comparator | Jul 2024 → Oct 2028 expected | adrenal cortex carcinoma, carcinoma of the ampulla of vater, duodenal adenocarcinoma, gastric adenocarcinoma +3 | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT06489808 Background | May 2024 → Dec 2026 expected | aggressive B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06277154 Background | Feb 2024 → Feb 2026 overdue | angiosarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibrosarcoma +7 | HRYZ Biotech Co. | Recruiting | No outcome recorded |
| Phase 2 | NCT05926492 Background | Jan 2024 → Jul 2025 overdue | osteosarcoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT05576532 Background | Jan 2023 → Oct 2024 | T-lymphoblastic lymphoma, refractory precursor T-lymphoblastic lymphoma/leukemia | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT05221645 Background | Jun 2022 → May 2026 overdue | diffuse large B-cell lymphoma | University of Southampton | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05348213 Background | May 2022 → Jun 2025 overdue | diffuse large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05277480 Background | Mar 2022 → Jun 2023 | poisoning | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05124951 Background | Sep 2021 → Oct 2026 expected | childhood central nervous system germ cell tumor | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04589754 Background | Jul 2021 → Dec 2025 overdue | soft tissue sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT04570423 Background | May 2021 → Oct 2027 expected | cancer, lymphoma | Spectrum Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT04824352 Background | Apr 2021 → Apr 2026 | poisoning | Peking University People's Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT04189952 Background | Sep 2020 → Jun 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma | University of Miami | Terminated | No outcome recorded |
| Phase 2 | NCT04699214 Comparator | Sep 2020 → Aug 2023 | soft tissue sarcoma | Yong Chen | Unknown | No outcome recorded |
| Phase 2 | NCT04224337 Background | Jun 2020 → Aug 2023 | non-small cell lung carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04154189 Background | Mar 2020 → Jun 2022 | osteosarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04066920 Background | Oct 2019 → Sep 2021 | primary central nervous system lymphoma | Deok-Hwan Yang | Unknown | No outcome recorded |
| Phase 2 | NCT03736616 Background | Aug 2019 → Sep 2023 | diffuse large B-cell lymphoma | Swedish Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04126811 Comparator | Jun → Dec 2019 | soft tissue sarcoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03643133 Background | Oct 2018 → Sep 2026 expected | osteosarcoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03418038 Background | Mar 2018 → Feb 2031 expected | Hodgkins lymphoma, chronic myelomonocytic leukemia, clonal hematopoiesis of indeterminate potential, diffuse large B-cell lymphoma +1 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT02808247 Comparator | Jul 2017 → Nov 2020 | soft tissue sarcoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 2 | NCT03121833 Background | May 2017 → Dec 2019 | soft tissue sarcoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03077828 Background | Apr 2017 → Dec 2020 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | Northwestern University | Unknown | No outcome recorded |
| Phase 2 | NCT03105596 Background | Apr 2017 → Sep 2018 | B-cell non-Hodgkin lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT02732015 Background | Oct 2016 → Jul 2020 | sarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02856997 Background | Sep 2016 → Mar 2019 | peripheral T-cell lymphoma, not otherwise specified | Yuankai Shi | Unknown | No outcome recorded |
| Phase 2 | NCT02014831 Background | Feb 2016 | squamous cell carcinoma of penis | Centre Leon Berard | Withdrawn | No outcome recorded |
| Phase 2 | NCT02638428 Background | Dec 2015 → Dec 2021 | childhood acute myeloid leukemia | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02592876 Background | Oct 2015 → Apr 2018 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02329080 Background | Dec 2014 → Aug 2019 | diffuse large B-cell lymphoma | International Extranodal Lymphoma Study Group (IELSG) | Completed | No outcome recorded |
| Phase 2 | NCT01946529 Comparator | Dec 2013 → Aug 2015 overdue | Ewing sarcoma, desmoplastic small round cell tumor | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01979536 Background | Nov 2013 → Mar 2021 | ALK-positive anaplastic large cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01864109 Background | May 2013 → May 2027 expected | Ewing sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01453205 Background | Feb 2012 → Jul 2016 | diffuse large B-cell lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT01329900 Background | Aug 2011 → Jul 2019 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02412267 Background | Apr 2011 → Dec 2015 | diffuse large B-cell lymphoma | National Cancer Centre, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT01172912 Background | Oct 2010 → Oct 2012 | central nervous system neoplasm, extragonadal germ cell tumor, testicular germ cell tumor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 2 | NCT01055314 Background | Jan 2010 → Jun 2016 | alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00967369 Background | Aug 2009 → May 2018 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00823719 Background | May 2009 → Jul 2011 | diffuse large B-cell lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00864318 Background | Mar 2009 → Oct 2020 | germ cell tumor | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 2 | NCT00809341 Comparator | Jan 2009 → Apr 2014 | non-Hodgkin lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT00643565 Background | Jul 2008 → May 2015 | sarcoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00836173 Background | Jul 2008 → May 2012 | diffuse large B-cell lymphoma | Loyola University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00667342 Background | Jun 2008 → Aug 2014 | osteosarcoma, undifferentiated high grade pleomorphic sarcoma of bone | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00636311 Background | Feb → Apr 2008 | Hodgkins lymphoma | Istituto Clinico Humanitas | Completed | No outcome recorded |
| Phase 2 | NCT00529503 Background | Sep 2007 → Dec 2009 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01458730 Background | May 2007 → Oct 2010 | central nervous system non-hodgkin lymphoma | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT00504751 Background | May 2007 → Dec 2010 | non-Hodgkin lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00392990 Background | Feb 2007 → Dec 2011 | lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00381940 Background | Jan 2007 → Jun 2008 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, adult nodular lymphocyte predominant Hodgkin lymphoma, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00324467 Comparator | Aug 2006 → Dec 2021 | diffuse large B-cell lymphoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT00267046 Background | Dec 2005 → Jul 2009 | chemotherapy-induced oral mucositis, sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00245011 Background | Oct 2004 → Oct 2008 | sarcoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00061893 Background | Apr 2004 → Apr 2008 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00499343 Background | Jan 2004 → Oct 2008 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00163761 Comparator | Dec 2002 → Feb 2008 | Hodgkins lymphoma, non-Hodgkin lymphoma | Bayside Health | Completed | No outcome recorded |
| Phase 2 | NCT01290120 Background | Nov 2002 → Jun 2014 | Burkitt lymphoma | Northern Italy Leukemia Group | Completed | No outcome recorded |
| Phase 2 | NCT00023998 Background | Jul 2001 → Nov 2005 | osteosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00004132 Background | Jan 2000 → May 2004 | chemotherapy-induced oral mucositis, leukemia, plasma cell neoplasm, poisoning +1 | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00005631 Background | Nov 1999 → Nov 2002 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004061 Background | May 1999 → May 2003 | chemotherapy-induced oral mucositis, leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00204646 Background | Feb 1999 → Dec 2006 | soft tissue sarcoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT00003575 Background | Jan 1999 → Apr 2002 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06820957 Background | Nov 2025 → Dec 2027 expected | CIC-rearranged sarcoma, Ewing sarcoma, round cell sarcoma with EWSR1-non-ETS fusion, sarcoma with BCOR genetic alterations +1 | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05991388 Background | May 2024 → May 2031 expected | B-cell non-Hodgkin lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02405676 Background | Jan 2015 → Dec 2023 overdue | B-cell non-Hodgkin lymphoma | Children's Cancer Group, China | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00691236 Background | May 2008 → May 2013 | osteosarcoma | Tata Memorial Hospital | Unknown | No outcome recorded |
| Phase 337 trials | ||||||
| Phase 3 | NCT07187960 Comparator | Nov 2025 → Oct 2028 expected | follicular lymphoma | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06792253 Comparator | Jan 2025 → Dec 2028 expected | relapsed/refractory diffuse large B-cell lymphoma | BeBetter Med Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06230224 Comparator | Feb 2024 → May 2028 expected | aggressive B-cell non-Hodgkin lymphoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05681260 Background | Feb 2023 → Dec 2026 expected | T-lymphoblastic lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
| Phase 3 | NCT05244642 Comparator | Feb 2022 → Dec 2025 | Hodgkins lymphoma | Akeso | Unknown | No outcome recorded |
| Phase 3 | NCT04342936 Comparator | Jul 2020 → Aug 2023 | classic Hodgkin lymphoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04044222 Background | Oct 2019 → Jul 2023 | classic Hodgkin lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03643276 Background | Jul 2018 → Jul 2028 expected | childhood acute lymphoblastic leukemia | Martin Schrappe | Recruiting | No outcome recorded |
| Phase 3 | NCT03479918 Comparator | Mar 2018 → Mar 2021 | high grade B-cell lymphoma | Elena N.Parovichnikova | Unknown | No outcome recorded |
| Phase 3 | NCT03391466 Comparator | Jan 2018 → Mar 2021 | diffuse large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 3 | NCT03206671 Background | Aug 2017 → Jun 2027 expected | B-cell non-Hodgkin lymphoma | University Hospital Muenster | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02703272 Background | Jul 2016 → Jun 2021 | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02393859 Comparator | Nov 2015 → Jul 2019 | acute lymphoblastic leukemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02842931 Comparator | Feb 2015 → Feb 2020 | diffuse large B-cell lymphoma | National Research Center for Hematology, Russia | Unknown | No outcome recorded |
| Phase 3 | NCT02306161 Background | Dec 2014 → Mar 2021 overdue | Ewing sarcoma, bone marrow cancer, metastatic malignant neoplasm, peripheral primitive neuroectodermal tumor of bone +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02112916 Background | Oct 2014 → Mar 2020 overdue | T-cell childhood acute lymphocytic leukemia, T-cell childhood lymphoblastic lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02531841 Comparator | Jul 2014 → Nov 2017 | diffuse large B-cell lymphoma | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 3 | NCT02049905 Comparator | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01710176 Comparator | Jun 2011 → Jun 2024 | soft tissue sarcoma | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase 3 | NCT01231906 Background | Nov 2010 → Mar 2020 | extraskeletal Ewing sarcoma, peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissues | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01117441 Background | Jun 2010 → Dec 2021 | leukemia | University Hospital Schleswig-Holstein | Completed | No outcome recorded |
| Phase 3 | NCT02063022 Comparator | Jan 2009 → Apr 2022 | Ewing sarcoma | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase 3 | NCT00796120 Comparator | Nov 2008 → Aug 2012 | sarcoma | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00470223 Background | Mar 2007 → Dec 2015 overdue | sarcoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03042429 Comparator | Jan 2007 → Dec 2016 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00334867 Background | Dec 2005 → Jan 2006 | sarcoma | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT00088530 Comparator | Jul 2004 → Feb 2010 | non-Hodgkin lymphoma | CTI BioPharma | Completed | No outcome recorded |
| Phase 3 | NCT00072215 Background | Apr 2004 → Apr 2005 | extragonadal germ cell tumor, testicular germ cell tumor | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 3 | NCT00278278 Background | Sep 2003 → Mar 2010 | central nervous system neoplasm | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| Phase 3 | NCT00022737 Background | Oct 2002 → Oct 2006 | childhood acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT02288741 Background | Aug 2001 → Sep 2012 | plasma cell myeloma | WiSP Wissenschaftlicher Service Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00006708 Background | Oct 2000 → Nov 2002 | lymphoma | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT00012051 Background | Sep 2000 → Oct 2007 | lymphoma | Commissie Voor Klinisch Toegepast Onderzoek | Completed | No outcome recorded |
| Phase 3 | NCT00006455 Background | Nov 1999 → Jan 2009 | lymphoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 3 | NCT00002816 Background | Dec 1996 → Nov 2002 | acute leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00162695 Background | Jul 1995 → ? | rhabdomyosarcoma | Gustave Roussy, Cancer Campus, Grand Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00002898 Background | Jan 1995 → Dec 2009 | undifferentiated high grade pleomorphic sarcoma of bone | International Society of Pediatric Oncology | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05518383 Background | May 2022 → May 2025 overdue | Burkitt lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
| Phase 4 | NCT04134247 Background | Nov 2019 → Nov 2021 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03558412 Background | Jun 2018 → Dec 2019 | T-lymphoblastic lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06302465 Comparator | May 2024 → Nov 2026 expected | bone cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT04690231 Background | Dec 2020 → Mar 2021 | poisoning | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT03360760 Background | Aug 2018 → Feb 2020 | bone osteosarcoma | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT01446809 Background | Apr 2012 → Jan 2019 | soft tissue sarcoma | University of Washington | Completed | No outcome recorded |
| — | NCT00410488 Comparator | Dec 2006 → Jun 2011 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00346125 Comparator | Apr 2006 → Jul 2013 | sarcoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| — | NCT00283621 Background | Jun 2003 → Apr 2006 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00541411 Background | Jun 2003 → Jun 2013 | Ewing sarcoma | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 463 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ifosfamide | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗455“Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours...” NCT02856997 ↗ “treatment consisted of six to eight rituximab infusions and four to six courses of intensive chemotherapy (attenuated in patients aged >55 years) with high-dose methotrexate,...” PMID 23753030 ↗ Jun 2013 “Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte...” NCT01458730 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗ “The histological type of squamous cells carcinoma, which is the large majority of penile cancer, led Pagliaro et al. [10] to explore a combination of Paclitaxel, Ifosfamide and...” NCT02014831 ↗ “Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care...” NCT04570423 ↗ “Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2...” NCT01667302 ↗ “Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between...” NCT03651375 ↗ “Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide...” NCT02063022 ↗ “This trial is to evaluate the efficacy of concurrent chemoradiotherapy with cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized NK/T-cell...” NCT00418535 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.” NCT05050630 ↗ “Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)” NCT00392990 ↗ “AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W” NCT04699214 ↗ “pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS).” PMID 36239473 ↗ Dec 2022 “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)” NCT02288741 ↗ “Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2).” NCT06438614 ↗ “Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration” NCT00541840 ↗ “compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China” NCT04294511 ↗ “Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)” NCT04307277 ↗ “Phase II Trial of Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin (GIFOX-B)in Untreated NK/T Cell Lymphoma” NCT02808091 ↗ “Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)” NCT06593899 ↗ “IVE, ifosfamide 2000 mg/m2 on days 1-3, epirubicin 70 mg/m2 on day 1, and etoposide 100 mg/m2 on days 1-3 every 21 days” PMID 32349779 ↗ Apr 2020 “patients with metastatic RMS received four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin” PMID 35709412 ↗ Jun 2022 “epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day” NCT03815474 ↗ “R-ICE:rituximab 375mg/m\^2 before chemotherapy, ifosfamide 5g/m\^2 24 hours continuous infusion (CI) on Day 2+mesna” NCT03391466 ↗ “* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).” NCT01696669 ↗ “High grade LPS: ADM (doxorubicin) 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m3 Q3 weeks.” NCT04031677 ↗ “Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;” NCT04881838 ↗ “ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1” NCT01382030 ↗ “ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle” NCT00823719 ↗ “oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy” NCT05576532 ↗ “PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen” NCT04860674 ↗ “TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle.” NCT06418789 ↗ “Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles.” NCT06156410 ↗ “SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy” PMID 35708709 ↗ Jul 2022 “Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin.” NCT06333314 ↗ “Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2” NCT03643133 ↗ “IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle” NCT03212937 ↗ “Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration” NCT06699472 ↗ “vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine” PMID 22652183 ↗ May 2012 “Four drugs will be adriamycin, high-dose methotrexate, cisplatin, ifosfamide.” NCT03390946 ↗ “* Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)” NCT02371161 ↗ “2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide)” NCT04838652 ↗ “IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours.” NCT01361191 ↗ “ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3” NCT01453205 ↗ “camrelizumab in combination with Liposome doxorubicin and Ifosfamide” NCT04606108 ↗ “R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide.” NCT03450343 ↗ “IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w” NCT04824352 ↗ “TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)” NCT06816771 ↗ “cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine” NCT03042429 ↗ “VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)” NCT01083342 ↗ “Ifosfamide 2 g/m2 IV over 3 hours on Days 10, 12, and 14,” NCT05705687 ↗ “1 gm/m2/day ifosfamide by continuous intravenous infusion” NCT02235701 ↗ “Etoposide + Ifosfamide (IFO) + Carboplatin] ± Rituximab” NCT06520163 ↗ “ifosfamide at a dose of 1200 mg/m² from day 2 to day 5” NCT06341998 ↗ “Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W” NCT04151810 ↗ “Ifosfamide continuous infusion + Mesna 5/m2/24hr day2” NCT01226849 ↗ “Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2” NCT01459484 ↗ “Rituximab + Ifosfamide + Etoposide + 1 Growth Factor” NCT00499343 ↗ “Adriamycin and Ifosfamide Combined With Sintilimab” NCT04589754 ↗ “apatinib po； ifosfamide ivgtt ; etoposide ivgtt .” NCT05277480 ↗ “Regimen B :IVAC:ifosfamide,etoposide，cytarabine.” NCT03558412 ↗ “ifosfamide 1g/m2, ivg, d1-4, given over 4 hours” NCT03105596 ↗ “Ifosfamide 12-15 g/m² total dose intravenously” NCT07142863 ↗ “Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days” NCT02842931 ↗ “Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days” NCT03479918 ↗ “Ifosfamide: 1.8 g/m2 (days 1, 2, 3, 4, 5)” NCT05827549 ↗ “Adriamycin + Cisplatinum and Ifosfamide” NCT00691236 ↗ “Paclitaxel, ifosfamide, and cisplatin” NCT02817958 ↗ “ifosfamide 1000 mg/m2/D from D1 to D5” NCT00970385 ↗ “Ifosfamide, IV, D15 to D19, 1.8g/m²/d” NCT03011528 ↗ “Pirarubicin (THP) + Ifosfamide (IFO)” NCT03121833 ↗ “Ifosfamide 1500 mg/m²/d i.v. (d1-3)” NCT02531841 ↗ “ifosfamide 2 g/m(2) i.v. Days 3- 5” PMID 23242601 ↗ Dec 2012 “ifosfamide 2000 mg/m2 i.v. d 15-17” NCT00517894 ↗ “ifosfamide 1.2g/m2 iv on days 3-5” NCT02560441 ↗ “Ifosfamide 1200 mg/m2 at days 1-4” NCT01333605 ↗ “ifosfamide 1000 mg/m 2 days 1 - 3” NCT03154918 ↗ “a 24-hour infusion of Ifosfamide” NCT00836173 ↗ “Idarubicin, Ifosfamide, Imatinib” NCT02788201 ↗ “ifosfamide, 1.67 g/m² IV day1\~3” NCT02445404 ↗ “ifosfamide: 2 g/m2 IV days 1-3” NCT01576692 ↗ “Ifosfamide; 2.5g/m2, day 8-12” NCT05926492 ↗ “I = Ifosfamide 2400 mg/m2/day” NCT04351308 ↗ “Ifosfamide 1500mg/m2 IV D1-3” NCT05348213 ↗ “ICE: Ifosfamide 1g/m２，d1-4” NCT04134247 ↗ “Ifosfamide 3.75 g/m2 on D2” NCT04066920 ↗ “Ifosfamide, 2400 mg/m²/d” NCT01966913 ↗ “ifosfamide 1.0g/m2 D1-4” NCT05244642 ↗ “Drug: Ifosfamide” NCT03206671 ↗ |
| Known as | Ifex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Known as | IFF | “The IVAC chemotherapy regimen comprises ifosfamide (IFF) IV over 1 hour and etoposide IV over 1 hour on days 1-5 and ARA-C IV over 3 hours on days 1 and 2.” NCT00040690 ↗3“ifosfamide (IFF) IV over 1 hour on days 1-5” NCT00006455 ↗ “Ifosfamide, IFF, NSC-109724;” NCT00001300 ↗ “IFF Ifosfamide, NSC-109724” NCT00002565 ↗ |
| Known as | IFO | “AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W” NCT04699214 ↗5“pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS).” PMID 36239473 ↗ Dec 2022 “Envafolimab combined with an AI regimen: liposomal doxorubicin 35 mg/m² on day 1; IFO 2.5 mg/m² on days 1-3, intravenous infusion, every 3 weeks.” NCT07243626 ↗ “Etoposide + Ifosfamide (IFO) + Carboplatin] ± Rituximab” NCT06520163 ↗ “Ifosfamide (IFO) 3 g/m2/day on days 1 to 3” NCT06849986 ↗ “Pirarubicin (THP) + Ifosfamide (IFO)” NCT03121833 ↗ |
| Known as | Ifosfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Known as | Ifosfamide - Ifex | “Ifosfamide - Ifex” NCT00093509 ↗ |
| Known as | Ifosphamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168980 ↗ |
| Known as | Ifsofamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Known as | Iphosphamid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05049473 ↗ |
| Known as | isocyclophosphamide | “Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable...” NCT06684327 ↗ |
| Known as | Isophosphamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05784987 ↗ |
| Known as | Mitoxana | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Known as | MJF 9325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Known as | NSC-109724 | “Ifosfamide, IFF, NSC-109724;” NCT00001300 ↗1“IFF Ifosfamide, NSC-109724” NCT00002565 ↗ |
| Known as | Z-4942 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1024 ↗ |
| Action | Inhibit | “Ifosfamide is designed to stop the growth of cancer cells, which may cause the cells to die.” NCT00673179 ↗ |
| Modality | Small molecule | “structural analogue of cyclophosphamide” NCT06528496 ↗ |
| Route | Intravenous | “Regimen B: Patients receive etoposide IV over 1 hour, followed immediately by ifosfamide IV over 1 hour on days 1-5.” NCT00002466 ↗ |